Mesa Laboratories, Inc’s recently made public that its President and CEO Owens Gary M unloaded Company’s shares for reported $0.19 million on Jun 16 ’25. In the deal valued at $97.12 per share,1,939 shares were sold. As a result of this transaction, Owens Gary M now holds 45,824 shares worth roughly $2.63 million.
Then, Archbold Brian David sold 472 shares, generating $45,840 in total proceeds. Upon selling the shares at $97.12, the SVP Operations now owns 558 shares.
Before that, Sakys John sold 642 shares. Mesa Laboratories, Inc shares valued at $62,350 were divested by the CFO at a price of $97.12 per share. As a result of the transaction, Sakys John now holds 12,865 shares, worth roughly $0.74 million.
Wells Fargo initiated its Mesa Laboratories, Inc [MLAB] rating to an Underweight in a research note published on August 28, 2024; the price target was $120. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who increased its forecast for the stock in early January from “an In-line” to “an Outperform”. Evercore ISI also remained covering MLAB and has decreased its forecast on January 04, 2021 with a “an In-line” recommendation from previously “an Outperform” rating. KeyBanc Capital Markets started covering the stock on November 10, 2020. It rated MLAB as “a Sector weight”.
Price Performance Review of MLAB
On Tuesday, Mesa Laboratories, Inc [NASDAQ:MLAB] saw its stock fall -24.92% to $57.44. Over the last five days, the stock has lost -25.19%. Mesa Laboratories, Inc shares have fallen nearly -48.27% since the year began. Nevertheless, the stocks have fallen -56.44% over the past one year.
How much short interest is there in Mesa Laboratories, Inc?
A steep rise in short interest was recorded in Mesa Laboratories, Inc stocks on 2025-07-15, growing by 68784.0 shares to a total of 0.25 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 0.18 million shares. There was a rise of 27.17%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 02, 2020 when JP Morgan began covering the stock and recommended ‘”a Neutral”‘ rating along with a $260 price target.
